Lv12
10 积分 2022-10-07 加入
Abstract B123: Mechanism of action of ivonescimab (AK112/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects
6小时前
求助中
MA06.05 A Phase II Study of Lorlatinib in Advanced ROS1+ NSCLC Pre-Treated with Crizotinib and Platinum-Based Chemotherapy
1天前
已完结
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
1个月前
已完结
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
2个月前
已完结
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study
2个月前
已完结
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update
2个月前
已关闭
Immune Checkpoint Inhibitor–Induced Cardiotoxicity A Systematic Review and Meta-Analysis
2个月前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
3个月前
已完结
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS)
3个月前
已完结
Real‐world data on ALK rearrangement test in Chinese advanced non‐small cell lung cancer (RATICAL): a nationwide multicenter retrospective study
3个月前
已完结
皖公网安备34019202002308
